Figure S1. First Round Secondary Screening: Competitive-ABPP profiling with recombinant LYPLA1 (human) and endogenous LYPLA1 and LYPLA2 (mouse brain soluble proteome): 20 μM Test Compound.
Figure S1. First Round Secondary Screening: Competitive-ABPP profiling with recombinant LYPLA1 (human) and endogenous LYPLA1 and LYPLA2 (mouse brain soluble proteome): 20 μM Test Compound.

Figure S1First Round Secondary Screening: Competitive-ABPP profiling with recombinant LYPLA1 (human) and endogenous LYPLA1 and LYPLA2 (mouse brain soluble proteome): 20 μM Test Compound

Quantification of rhLYPLA1 inhibition in AID 493105; 20 nM recombinant human LYPLA1 doped into 1 mg/mL mouse brain soluble proteome; 20 μM inhibitor treatment for 30 min followed by FP-Rh labeling for 30 min, SDS-PAGE and in-gel fluorescent imaging. See Table S1 for compound SIDs and structures.

From: Optimization and characterization of a triazole urea dual inhibitor for lysophospholipase 1 (LYPLA1) and lysophospholipase 2 (LYPLA2)

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.